TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

TMDX 12.23.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-13
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur TMDX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report
  • 12.23.2024 - TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.06.2024 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors

ANDOVER, Mass.,Dec. 23, 2024/PRNewswire/ --TransMedics Group, Inc.("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rdAnnualJ.P. Morgan Healthcare Conference. The presentation will take place onMonday, January 13, 2025, at2:15 p.m. Pacific Standard Time/5:15 p.m. Eastern Standard Time.

(PRNewsfoto/TransMedics, Inc.)

Event: 43rdAnnualJ.P. Morgan Healthcare ConferenceDate:Monday, January 13, 2025Time:2:15 p.m. PST

A live and archived webcast of the presentation will be available on the "Investors" section of theTransMedicswebsite athttps://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.

AboutTransMedics Group, Inc.TransMedicsis the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered inAndover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:Brian JohnstonLaine Morgan332-895-3222Investors@transmedics.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-43rd-annual-jp-morgan-healthcare-conference-302338418.html

SOURCETransMedics Group, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com